Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310095) titled 'A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Xian-Janssen Pharmaceutical Ltd.
Condition:
Crohn Disease
Intervention:
Drug: Guselkumab (GUS)
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: January 16, 2026
Target Sample Size: 78
To know more, visit https://clinicaltrials.gov/study/NCT07310095
Disclaimer: Curated by HT Syndication....